Vincristine exacerbates asymptomatic Charcot-Marie-Tooth disease with a novel EGR2 mutation

Neurogenetics

Volumn 13, Issue 1, 2012, Pages 77-82

  Nakamura, Tomonori ^a   Hashiguchi, Akihiro ^a   Suzuki, Shinsuke ^a   Uozumi, Kimiharu ^a   Tokunaga, Shoko ^a   Takashima, Hiroshi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Charcot Marie Tooth disease; DNA chip; Early growth response 2; Vincristine induced neuropathy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 2; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; EGR2 PROTEIN, HUMAN;

ADULT; AREFLEXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DNA DETERMINATION; DNA SEQUENCE; ELECTROPHYSIOLOGY; FEMALE; GENE MUTATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MOTHER; MUSCLE WEAKNESS; NERVE CONDUCTION; PARESTHESIA; PRIORITY JOURNAL; WALKING DIFFICULTY; AMINO ACID SEQUENCE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETICS; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHARCOT-MARIE-TOOTH DISEASE; DNA MUTATIONAL ANALYSIS; EARLY GROWTH RESPONSE PROTEIN 2; FEMALE; HEREDITARY SENSORY AND MOTOR NEUROPATHY; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEURAL CONDUCTION; SEQUENCE ALIGNMENT; VINCRISTINE; YOUNG ADULT;

EID: 84861318858     PISSN: 13646745     EISSN: 13646753     Source Type: Journal    
DOI: 10.1007/s10048-012-0313-1     Document Type: Article

References (30)

1. Weiss HD, Walker MD, Wiernik PH (1974) Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med 291:127-133
2. Trobaugh-Lotrario AD, Smith AA, Odom LF (2003) Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol 40:39-43 (Pubitemid 35340566)
3. Weimer LH, Podwall D (2006) Medication-induced exacerbation of neuropathy in Charcot-Marie-Tooth disease. J Neurol Sci 242:47-54
4. Birouk N, Gouider R, Le Guern E, Gugenheim M, Tardieu S, Maisonobe T, Le Forestier N, Agid Y, Brice A, Bouche P (1997) Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 120:813-823 (Pubitemid 27222986)
5. Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K, Russo P, Kennedy S, Teebi AS, Scavina M, Williams LL, Mancias P, Butler IJ, Krajewski K, Shy M, Lupski JR (2002) Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 51:190-201 (Pubitemid 34111441)
6. Yerushalmi R, Levi I, Wygoda M, Ifergane G, Wirguin I (2007) Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease? J Peripher Nerv Syst 12:139-141 (Pubitemid 46906336)
7. Neumann Y, Toren A, Rechavi G, Seifried B, Shoham NG, Mandel M, Kenet G, Sharon N, Sadeh M, Navon R (1996) Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease. Med Pediatr Oncol 26:280-283
8. Mercuri E, Poulton J, Buck J, Broadbent V, Bamford M, Jungbluth H, Manzur AY, Muntoni F (1999) Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. Arch Dis Child 81:442-443 (Pubitemid 29501382)
9. Uno S, Katayama K, Dobashi N, Hirano A, Ogihara A, Yamazaki H, Usui N, Kobayashi T, Inoue K, Kuraishi Y (1999) Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease. Rinsho Ketsueki 40:414-419
10. Hildebrandt G, Holler E, Woenkhaus M, Quarch G, Reichle A, Schalke B, Andreesen R (2000) Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol 11:743-747
11. Naumann R, Mohm J, Reuner U, Kroschinsky F, Rautenstrauss B, Ehninger G (2001) Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol 115:323-325
12. Cil T, Altintas A, Tamam Y, Battaloglu E, Isikdogan A (2009) Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy). J Pediatr Hematol Oncol 31:787-789
13. Ajitsaria R, Reilly M, Anderson J (2008) Uneventful administration of vincristine in Charcot-Marie-Tooth disease type 1X. Pediatr Blood Cancer 50:874-876 (Pubitemid 351354805)
14. Nishikawa T, Kawakami K, Kumamoto T, Tonooka S, Abe A, Hayasaka K, Okamoto Y, Kawano Y (2008) Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 30:519-521
15. Porter CC, Carver AE, Albano EA (2009) Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer 52:298-300
16. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J (2001) EGR2 mutations in inherited neuropathies dominantnegatively inhibit myelin gene expression. Neuron 30:355-368 (Pubitemid 32530581)
17. Scherer SS (1997) The biology and pathobiology of Schwann cells. Curr Opin Neurol 10:386-397
18. Niemann A, Berger P, Suter U (2006) Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromolecular Med 8:217-242
19. Swiatek PJ, Gridley T (1993) Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20. Gene Dev 7:2071-2084 (Pubitemid 23336135)
20. Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi AB, Seitanidou T, Babinet C, Charnay P (1994) Krox-20 controls myelination in the peripheral nervous system. Nature 371:796-799 (Pubitemid 24333867)
21. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, Lupski JR (1998) Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 18:382-384 (Pubitemid 28158170)
22. Timmerman V, De Jonghe P, Ceuterick C, De Vriendt E, Lofgren A, Nelis E, Warner LE, Lupski JR, Martin JJ, Van Broeckhoven C (1999) Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology 52:1827-1832 (Pubitemid 29260896)
23. Warner LE, Svaren J, Milbrandt J, Lupski JR (1999) Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies. Hum Mol Genet 8:1245-1251 (Pubitemid 29328993)
24. Boerkoel C, Takashima H, Bacino C, Daentl D, Lupski J (2001) EGR2 mutation R359W causes a spectrum of Dejerine-Sottas neuropathy. Neurogenetics 3:153-157 (Pubitemid 33739054)
25. Yoshihara T, Kanda F, Yamamoto M, Ishihara H, Misu K, Hattori N, Chihara K, Sobue G (2001) A novel missense mutation in the early growth response 2 gene associated with late-onset Charcot-Marie-Tooth disease type 1. J Neurol Sci 184:149-153 (Pubitemid 32178268)
26. Mikesova E, Huhne K, Rautenstrauss B, Mazanec R, Barankova L, Vyhnalek M, Horacek O, Seeman P (2005) Novel EGR2 mutation R359Q is associated with CMT type 1 and progressive scoliosis. Neuromuscul Disord 15:764-767 (Pubitemid 41476291)
27. Jang SW, LeBlanc SE, Roopra A, Wrabetz L, Svaren J (2006) In vivo detection of Egr2 binding to target genes during peripheral nerve myelination. J Neurochem 98:1678-1687 (Pubitemid 44200456)
28. LeBlanc SE, Ward RM, Svaren J (2007) Neuropathy-associated Egr2 mutants disrupt cooperative activation of myelin protein zero by Egr2 and Sox10. Mol Cell Biol 27:3521-3529 (Pubitemid 46685226)
29. Jang SW, Svaren J (2009) Induction of myelin protein zero by early growth response 2 through upstream and intragenic elements. J Biol Chem 284:20111-20120
30. Jones EA, Lopez-Anido C, Srinivasan R, Krueger C, Chang LW, Nagarajan R, Svaren J (2011) Regulation of the PMP22 gene through an intronic enhancer. J Neurosci 31:4242-4250